Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488975 | 0.76 | ABCB1 (0.33) | ABCB1 | |
| SCHEMBL17966435 | 0.67 | ABCB1 (0.33) | ABCB1 | |
| SCHEMBL6439630 | 0.64 | ABCB1 (0.36) | ABCB1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6439632 | 0.64 | ABCB1 (0.36) | ABCB1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13290576 | 0.64 | ABCB1 (0.36) | ABCB1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12871198 | 0.60 | — | — | |
| SCHEMBL15912373 | 0.59 | ABCB1 (0.32) | ABCB1 | |
| SCHEMBL1106157 | 0.59 | ALOX5 (0.33) | ABCB1 | |
| SCHEMBL17677004 | 0.58 | CREBBP (0.58) | ALDH1A1 | |
| SCHEMBL23596518 | 0.57 | TSHR (0.48) | ABCB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981910-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2018-05-29 | — | — | US | disclosed |
| US-20180099932-A1 | Substituted Pyrrolidines and Methods of Use | GALAPAGOS NV (BE) | 2018-04-12 | — | — | US | disclosed |
| US-20180099931-A1 | Substituted Pyrrolidines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099931-A1 | Substituted Pyrrolidines and Methods of Use | CFTR, PKD1, PKD2 | ABCB1 55/4885ALDH1A1 586/4885CYP1A2 426/4885 |
| US-20180099932-A1 | Substituted Pyrrolidines and Methods of Use | CFTR, PKD1, PKD2 | ABCB1 52/4885ALDH1A1 563/4885CYP1A2 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.